Intensity Therapeutics, Inc. (INTS): R&D Expense
$6.79M
Year ended 2025-12-31
$6.08M
Trailing 12 months to 2026-06-30
+9.8%
3-year compound annual growth
| Period ended | R&D Expense | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $6.79M | -35.4% | 2026-03-27, From 2025-01-01 |
| 2024-12-31 | $10.50M | +119.3% | 2026-03-27, From 2024-01-01 |
| 2023-12-31 | $4.79M | -6.7% | 2025-03-13, From 2023-01-01 |
| 2022-12-31 | $5.13M | n/a | 2024-03-14, From 2022-01-01 |
R&D Expense at similar companies
| Company | Year ended | R&D Expense | Change YoY |
|---|---|---|---|
| Intensity Therapeutics, Inc. (INTS) | 2025-12-31 | $6.79M | -35.4% |
| MiNK Therapeutics, Inc. (INKT) | 2025-12-31 | $5.76M | -9.1% |
| BioAtla, Inc. (BCAB) | 2025-12-31 | $43.57M | -30.9% |
| Entera Bio Ltd. (ENTX) | 2025-12-31 | $6.00M | +33.5% |
| Scinai Immunotherapeutics Ltd. (SCNI) | 2025-12-31 | $2.37M | -57.2% |
| Outlook Therapeutics, Inc. (OTLK) | 2025-09-30 | $27.18M | -34.9% |
| Curis Inc (CRIS) | 2025-12-31 | $28.25M | -26.7% |
| Dyadic International Inc (DYAI) | 2025-12-31 | $2.15M | +5.4% |
| Atara Biotherapeutics, Inc. (ATRA) | 2025-12-31 | $37.45M | -75.3% |
Compare INTS, INKT, BCAB, ENTX side by side · Screen every company in Biological Products, (No Diagnostic Substances) ↗